Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
February 19 2020 - 8:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
present at the Cowen and Company 40th Annual Health Care
Conference in Boston on Wednesday, March 4, 2020, at
9:20 a.m. EST.
A live audio webcast of the presentation will be accessible from
the Investors page of Galera’s website, investors.galeratx.com. An
archived version of the webcast will be available in the News &
Events section of the Investors page of Galera’s website for 30
days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing a pipeline of
novel, proprietary therapeutics that have the potential to
transform radiotherapy in cancer. Galera’s lead product candidate
is avasopasem manganese (GC4419), a highly selective small molecule
superoxide dismutase (SOD) mimetic initially being developed for
the reduction of radiation-induced severe oral mucositis (SOM).
Avasopasem manganese is being studied in the Phase 3 ROMAN trial
for its ability to reduce the incidence, severity and duration of
radiation-induced SOM in patients with locally advanced head and
neck cancer being treated with radiotherapy, its lead indication,
and in the Phase 2a trial for its ability to reduce the incidence
of radiation-induced esophagitis in patients with lung cancer. The
FDA granted Fast Track and Breakthrough Therapy designations to
avasopasem manganese for the reduction of SOM induced by
radiotherapy. Galera is developing a second product candidate,
GC4711, which successfully completed a Phase 1 trial in healthy
volunteers. Galera is headquartered in Malvern, PA. For more
information, please visit www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
Chiara RussoSolebury
Trout617-221-9197crusso@soleburytrout.com
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024